Benefits
Mood Support (Subclinical / Integrative)
A small open-label trial (Sartori, 1986) and integrative clinical experience suggest low-dose lithium orotate may support mood stability and a sense of calm. The evidence base is very limited and largely anecdotal or from small uncontrolled studies, and it is not equivalent to prescription lithium for bipolar disorder.
Neuroprotection (Theoretical)
Lithium has well-characterized neuroprotective actions in the laboratory and at prescription doses: it raises BDNF, inhibits the enzyme GSK-3β, and promotes neurogenesis. Whether the much lower amounts in a lithium orotate supplement deliver a meaningful neuroprotective effect in people is unproven. Population data on environmental lithium intake are suggestive but cannot establish cause and effect.
Cognitive Function (Theoretical)
Prescription lithium has measurable effects on the brain, but the cognitive effects of low supplemental doses of lithium orotate are not established. Some integrative practitioners use it for focus, anxiety, or mild age-related cognitive changes; the supporting evidence is limited.
Population Studies: Suicide and Lithium in Drinking Water
A number of population (ecological) studies, including a 2020 systematic review and meta-analysis, report an inverse association between the natural lithium content of drinking water and rates of suicide, and separately with dementia incidence. This hints that very low environmental lithium exposure may carry public-health benefits, but ecological data cannot prove causation, and there is essentially no trial evidence that taking a lithium supplement reproduces these population-level patterns.
Alzheimer's Disease Research
A one-year randomized trial of low-dose lithium carbonate (300 mg per day) in people with mild cognitive impairment showed reduced tau phosphorylation and a trend toward preserved cognition, and a separate trial of microdose lithium (300 micrograms per day) reported stabilized cognition in Alzheimer's disease. These used pharmaceutical lithium rather than lithium orotate, so the results do not translate directly, but they sustain research interest in lithium for brain aging.
Mechanism of action
GSK-3β Inhibition
Lithium inhibits glycogen synthase kinase-3β (GSK-3β), with several downstream effects of interest in brain aging, including reduced tau hyperphosphorylation (relevant to Alzheimer's), increased Wnt signaling, and support for neurogenesis. The mechanism is well established, but the lithium concentrations that drive it are mainly reached with prescription doses.
BDNF Increase
Lithium raises brain-derived neurotrophic factor (BDNF), which supports neuroplasticity and the growth of new neurons. This is one of the mechanisms thought to underlie its mood-stabilizing effect at prescription doses.
Inositol Depletion
Lithium lowers inositol levels in the central nervous system, altering intracellular signaling. This is a long-standing proposed mechanism for its mood-stabilizing action in bipolar disorder.
Lithium Orotate Specific Pharmacology
The orotate carrier was originally claimed (by Hans Nieper in the 1970s) to improve lithium delivery into tissues compared with other lithium salts, but that claim has not been robustly replicated. At supplemental doses (about 5 to 20 mg of elemental lithium), blood lithium stays far below the prescription therapeutic range (0.4 to 1.2 mmol/L). A 2021 review re-examined the orotate question and judged the form plausible but still under-studied.
Clinical trials
Open-label trial of lithium orotate (about 150 mg per day, providing roughly 5 mg of elemental lithium) in people with alcohol dependence, followed for up to several years. Published in Alcohol.
42 people with alcoholism; open-label, no control group.
The author reported reductions in alcohol consumption and improved mood. This is the most cited human study of lithium orotate specifically, but its methodology is weak: it was open-label with no placebo or control arm, so it cannot establish efficacy on its own.
Randomized, placebo-controlled trial of lithium carbonate (300 mg per day) versus placebo over one year. Published in the British Journal of Psychiatry.
45 adults with amnestic mild cognitive impairment.
Lithium was associated with lower tau phosphorylation in cerebrospinal fluid and a trend toward better cognitive performance. It used pharmaceutical lithium at doses many times higher than a lithium orotate supplement, so the findings inform the lithium-and-brain hypothesis rather than lithium orotate directly.
Randomized, controlled study of microdose lithium (300 micrograms per day of lithium carbonate) versus placebo over 15 months. Published in Current Alzheimer Research.
Patients with Alzheimer's disease (small sample).
The microdose group showed stabilized cognitive scores while the placebo group declined. The dose here is far smaller than standard pharmaceutical lithium and closer to supplemental territory, which is part of why it draws interest, though the trial is small and needs replication.